About BioXcel Therapeutics, Inc.
https://www.bioxceltherapeutics.comBioXcel Therapeutics, Inc. is a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology.
CEO
Vimal D. Mehta
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2025-02-10 | Reverse | 1:16 |
ETFs Holding This Stock
Summary
Showing Top 2 of 2
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
Grade Summary
Showing Top 3 of 3
Price Target
Institutional Ownership
MILLENNIUM MANAGEMENT LLC
Shares:1.03M
Value:$1.96M
BLACKROCK INC.
Shares:440.69K
Value:$841.71K
OAKTREE CAPITAL MANAGEMENT LP
Shares:241.19K
Value:$460.67K
Summary
Showing Top 3 of 43
About BioXcel Therapeutics, Inc.
https://www.bioxceltherapeutics.comBioXcel Therapeutics, Inc. is a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $98K ▼ | $13.94M ▼ | $-30.91M ▼ | -31.54K% ▼ | $-2.18 ▲ | $-26.46M ▼ |
| Q2-2025 | $120K ▼ | $15.87M ▲ | $-19.19M ▼ | -15.99K% ▼ | $-2.45 ▼ | $-14.89M ▼ |
| Q1-2025 | $168K ▼ | $10.25M ▲ | $-7.25M ▲ | -4.32K% ▼ | $-1.5 ▲ | $-3.19M ▲ |
| Q4-2024 | $366K ▲ | $10.03M ▼ | $-10.86M ▲ | -2.97K% ▲ | $-3.57 ▲ | $-6.75M ▲ |
| Q3-2024 | $214K | $14.34M | $-13.65M | -6.38K% | $-5.15 | $-9.78M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $37.32M ▲ | $44.79M ▲ | $133.71M ▲ | $-88.92M ▲ |
| Q2-2025 | $17.43M ▼ | $25.79M ▼ | $133.46M ▲ | $-107.67M ▼ |
| Q1-2025 | $31.01M ▲ | $38.57M ▲ | $128.74M ▼ | $-90.17M ▲ |
| Q4-2024 | $29.85M ▼ | $38.34M ▼ | $131.44M ▼ | $-93.1M ▼ |
| Q3-2024 | $40.39M | $48.89M | $134.53M | $-85.63M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-30.91M ▼ | $-18.79M ▼ | $0 | $37.53M ▲ | $18.75M ▲ | $-18.79M ▼ |
| Q2-2025 | $-19.19M ▼ | $-12.57M ▼ | $0 | $137K ▼ | $-12.44M ▼ | $-12.57M ▼ |
| Q1-2025 | $-7.25M ▲ | $-12.04M ▲ | $0 | $13.2M ▲ | $1.16M ▲ | $-12.04M ▲ |
| Q4-2024 | $-10.86M ▲ | $-14.81M ▲ | $0 | $4.28M ▲ | $-10.53M ▲ | $-14.81M ▲ |
| Q3-2024 | $-13.65M | $-16.34M | $0 | $454K | $-15.88M | $-16.34M |
CEO
Vimal D. Mehta
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2025-02-10 | Reverse | 1:16 |
ETFs Holding This Stock
Summary
Showing Top 2 of 2
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
Grade Summary
Showing Top 3 of 3
Price Target
Institutional Ownership
MILLENNIUM MANAGEMENT LLC
Shares:1.03M
Value:$1.96M
BLACKROCK INC.
Shares:440.69K
Value:$841.71K
OAKTREE CAPITAL MANAGEMENT LP
Shares:241.19K
Value:$460.67K
Summary
Showing Top 3 of 43